TPA
TMO icon

Trivium Point Advisory’s Thermo Fisher Scientific TMO Stock Holding History

Trivium Point Advisory’s Portfolio TMO Stock Details TMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.15M Buy
8,277
+512
+7% +$246K 0.38% 68
2026
Q1 		$3.82M Sell
7,765
-494
-6% -$268K 0.69% 33
2025
Q4 		$4.79M Sell
8,259
-175
-2% -$99K 0.48% 57
2025
Q3 		$4.09M Sell
8,434
-252
-3% -$117K 0.42% 63
2025
Q2 		$3.52M Sell
8,686
-844
-9% -$353K 0.38% 68
2025
Q1 		$4.74M Sell
9,530
-956
-9% -$518K 0.59% 46
2024
Q4 		$5.46M Buy
10,486
+820
+8% +$451K 0.69% 35
2024
Q3 		$5.24M Sell
9,666
-768
-7% -$455K 0.73% 36
2024
Q2 		$5.77M Buy
10,434
+553
+6% +$317K 0.86% 26
2024
Q1 		$5.74M Buy
9,881
+193
+2% +$108K 1.24% 18
2023
Q4 		$5.14M Buy
9,688
+158
+2% +$76.5K 1.25% 18
2023
Q3 		$4.76M Buy
9,530
+50
+0.5% +$26.6K 1.31% 15
2023
Q2 		$4.95M Sell
9,480
-175
-2% -$94.4K 1.34% 14
2023
Q1 		$5.56M Buy
9,655
+155
+2% +$87.4K 1.5% 14
2022
Q4 		$5.08M Buy
9,500
+103
+1% +$54.6K 1.48% 12
2022
Q3 		$5.08M Buy
9,397
+219
+2% +$123K 1.58% 10
2022
Q2 		$5.08M Sell
9,178
-7
-0.1% -$3.85K 1.53% 13
2022
Q1 		$5.39M Buy
9,185
+270
+3% +$155K 1.2% 19
2021
Q4 		$5.95M Buy
8,915
+110
+1% +$68.7K 1.25% 16
2021
Q3 		$5.14M Sell
8,805
-45
-0.5% -$24.7K 1.22% 16
2021
Q2 		$4.46M Buy
8,850
+336
+4% +$159K 1.11% 19
2021
Q1 		$3.89M Sell
8,514
-148
-2% -$70.6K 1.05% 14
2020
Q4 		$4.33M Sell
8,662
-177
-2% -$83K 1.25% 12
2020
Q3 		$3.9M Buy
8,839
+337
+4% +$139K 1.38% 11
2020
Q2 		$3.25M Buy
8,502
+576
+7% +$193K 1.29% 13
2020
Q1 		$2.43M Sell
7,926
-506
-6% -$160K 1.25% 14
2019
Q4 		$2.74M Buy
8,432
+60
+0.7% +$18.2K 1.06% 15
2019
Q3 		$2.31M Sell
8,372
-325
-4% -$93.1K 1.06% 20
2019
Q2 		$2.55M Buy
8,697
+375
+5% +$103K 1.14% 14
2019
Q1 		$2.28M Sell
8,322
-20
-0.2% -$4.98K 1.06% 17
2018
Q4 		$1.87M Buy
+8,342
New +$1.96M 1.13% 24

Other funds holding TMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Trivium Point Advisory's TMO Position: Q2 2026 in Review

Trivium Point Advisory increased its Thermo Fisher Scientific (TMO) stake by 6.6% in Q2 2026, buying an estimated $246K and bringing the position to 8,277 shares worth $4.15M. The position accounts for 0.38% of the portfolio, ranked #68.

Trivium Point Advisory first reported a position in TMO in Q4 2018 and has held it in 31 quarters since. The position peaked at $5.95M in Q4 2021. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.

  • Trivium Point Advisory held 8,277 shares of Thermo Fisher Scientific worth $4.15M as of Q2 2026.
  • Trivium Point Advisory bought 512 Thermo Fisher Scientific shares in Q2 2026, an estimated $246K.
  • Thermo Fisher Scientific made up 0.38% of Trivium Point Advisory's portfolio in Q2 2026, its #68 holding.
  • Trivium Point Advisory first reported a position in Thermo Fisher Scientific in Q4 2018 and has held it in 31 quarters since.
  • Trivium Point Advisory's Thermo Fisher Scientific position peaked at $5.95M in Q4 2021.
  • 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.

Based on Trivium Point Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.